Novavax Quadrivalent VLP Influenza Vaccine

**Novavax Quadrivalent VLP Influenza Vaccine** is an investigational recombinant, quadrivalent seasonal influenza virus-like particle vaccine developed by Novavax for prevention of influenza. It comprises strain-specific VLPs representing four influenza strains, with each VLP displaying hemagglutinin and neuraminidase antigens. Vaccination is intended to induce antibody responses against both viral surface glycoproteins, supporting protection from influenza infection and associated illness. The candidate was evaluated in completed Phase 2 dose-ranging studies in healthy adults, including a 400-participant study in adults aged 18–49 years. ([ir.novavax.com](https://ir.novavax.com/press-releases/2015-07-30-Novavax-Announces-Positive-Data-From-Phase-2-Trial-of-Quadrivalent-Seasonal-Influenza-VLP))

Other names

Seasonal Influenza VLPQuadrivalent VLP Vaccinerecombinant quadrivalent seasonal influenza virus-like particle vaccine